Gout
Therapeutic area
Metabolic Disease
Rare disease
No
- Definition
- A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Gout
- Therapeutic area
- Metabolic Disease
- gout
- chronic gout
- tophaceous disease
- tophaceous gout
- gout
- gouty arthropathy
- All therapeutic areas
- Metabolic Disease
- Severity
- Mild
- MONDO ID
- MONDO:0005393
- Parent condition
- MONDO:0005066
Related records
Broader conditions (4)
- Disease
- Disease by developmental or physiological process
- Human disease
- Metabolic disease
Trials (312)
- A Clinical Trial of HEC93077 in Chinese Healthy Subjects and HUA Patients With Single or Multiple Dosing
- A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
- A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
- A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
- A Nurse Led Patient Management Programme to Improve Outcomes in Gout
- A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
- A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
- A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
- A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
- A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.
- A Pilot Study to Explore the Role of Gut Flora in Gout
- A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
- A Single Dose Study of SHR4640 in Healthy Male Volunteers
- A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
- A Study of Dotinurad Versus Allopurinol in Participants With Gout
- A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
- A Study of IN026 in Participants With Refractory Gout
- A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II
Approved drugs (21)
- Allopurinol
- Benzbromarone
- Canakinumab
- Cinchophen
- Colchicine
- Cortisone acetate
- Dexamethasone
- Dexamethasone sodium phosphate
- Febuxostat
- Indomethacin
- Lesinurad
- Naproxen
- Naproxen sodium
- Pegloticase
- Prednisolone
- Prednisone
- Probenecid
- Rasburicase
- Sulfinpyrazone
- Tisopurine
Drugs in development (29)
- Anakinra Phase 2
- Apremilast Phase 2
- Arhalofenate Phase 2
- Azathioprine Phase 2
- Betamethasone Phase 3
- Betamethasone dipropionate Phase 3
- Bucillamine Phase 2
- Celecoxib Phase 3
- Denosumab Phase 2
- Diacerein Phase 2
- Diclofenac sodium Phase 2
- Dotinurad Phase 3
- Esuberaprost Phase 3
- Isobromindione Phase 2
- Lansoprazole Phase 3
- Metformin Phase 2
- Methotrexate Phase 1
- Methylprednisolone acetate Phase 2
- Mycophenolate mofetil Phase 2
- Oxeglitazar Phase 1
Other linked drugs (2)
- Indoprofen
- Topiroxostat